Morgan Stanley Raises Recursion Price Target to $125.60
0h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
RXRXbiotechnology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Morgan Stanley announced on May 22, 2026, that it has increased its price target on shares of Recursion Pharmaceuticals (RXRX). The new target of $125.60 represents a significant upward revision for the clinical-stage biotechnology company. This adjustment contributed to positive momentum for RXRX stock, which traded at $125.60, up 2.67% on the day. The analyst action underscores growing institutional confidence in the firm's artificial intelligence-powered drug discovery pipeline. Morgan Stanley's own stock, trading at $201.03, also saw a gain of 1.65% as of 01:22 UTC today.
The upgrade arrives during a period of heightened investor interest in biotechnology stocks, particularly those leveraging advanced computational methods. The sector has been volatile, closely tracking macroeconomic sentiment and interest rate expectations. Recursion's platform uses AI to map complex biological relationships and accelerate the identification of new drug candidates, a field that has attracted substantial venture capital.
A key catalyst for this re-rating is likely recent positive preclinical or early clinical data from one of Recursion's lead programs. The company has multiple candidates in oncology and neuroscience, areas with high unmet medical need. Analyst targets often shift following data readouts that de-risk a company's technical approach and timeline to commercialization.
The last major analyst action on Recursion prior to this was a target increase by another firm in late 2025. That move followed the company's presentation of new biomarkers for a central nervous system disorder. The magnitude of Morgan Stanley's new target suggests a more profound conviction in the platform's commercial scalability.
Morgan Stanley's new price target of $125.60 implies a substantial potential upside from recent trading levels. The stock's daily trading range on the news was $125.11 to $127.98, indicating strong buying interest. The 2.67% gain for RXRX outperformed the broader healthcare sector ETF (XBI), which was up approximately 1.2% on the same day.
The revision places Recursion's implied market capitalization well above $20 billion, a significant milestone for a company still in the clinical trial phase. For comparison, large-cap pharmaceutical stocks like Merck (MRK) typically trade at price-to-earnings ratios below 15, while pre-revenue biotech firms are valued on pipeline potential. The trading volume for RXRX was more than double its 30-day average, confirming the market's attention to the development.
Analyst consensus for Recursion's 12-month price target has been climbing steadily. Prior to this update, the average target among covering firms was approximately $98. Morgan Stanley's new target now stands as one of the highest on Wall Street, representing a nearly 30% increase over the previous consensus average.
| Metric | Pre-Announcement (Approx.) | Post-Announcement |
|---|---|---|
| Morgan Stanley Price Target | $95 | $125.60 |
| RXRX Stock Price | $122.30 | $125.60 |
| Implied Upside | ~ -22% | ~ 0% (at current price) |
The raised target validates the entire AI-driven drug discovery subsector. Peers like Schrödinger (SDGR) and Relay Therapeutics (RLAY) may see increased investor interest as the model gains credibility. Companies providing underlying technology, such as Nvidia (NVDA) with its BioNeMo platform, also benefit from the sector's maturation. The flow of capital into early-stage biotech is a positive indicator for venture capital firms and specialized ETFs.
A counter-argument is that high valuations for pre-revenue biotechs are highly sensitive to clinical trial outcomes. A single negative data readout could rapidly erase gains supported by analyst optimism. The risk of clinical failure remains the primary overhang on such speculative assets.
Positioning data suggests that hedge funds had been increasing their short interest in RXRX ahead of this announcement. The sharp price move likely triggered a short squeeze, amplifying the upward pressure. Long-term holders, including specialized healthcare funds, are the primary beneficiaries of this revaluation.
The next significant catalyst for Recursion is its second-quarter earnings report, scheduled for late July or early August 2026. Management's commentary on cash runway and pipeline progress will be scrutinized. Key levels to watch for the stock include initial support near $120 and resistance around the session high of $127.98.
Investors should monitor presentations at upcoming medical conferences, such as the American Association for Cancer Research symposium in September. Data presentations for lead oncology candidates will be critical for sustaining the positive momentum. The company's collaboration with Bristol-Myers Squibb is another focal point, with potential milestone payments acting as near-term catalysts.
The broader market's appetite for risk assets will also influence RXRX. A rise in Treasury yields or a hawkish shift from the Federal Reserve could pressure high-growth, non-profitable tech and biotech stocks irrespective of company-specific news. The stock's correlation with the Nasdaq Biotech Index (NBI) remains high.
A price target increase from a major institution like Morgan Stanley signals enhanced confidence in a company's future earnings potential. It can directly influence buying activity from the firm's clients and other investors who track its research. The effect is often immediate, as seen with RXRX's 2.67% gain, but the long-term price depends on the company executing its business plan and meeting the expectations set by the analysis.
AI-driven drug discovery uses machine learning and computational biology to analyze vast datasets of biological information. The goal is to identify novel drug targets, predict compound effectiveness, and optimize clinical trial design much faster than traditional methods. This approach, central to Recursion's model, aims to reduce the high cost and long timelines typically associated with pharmaceutical research, which often exceeds a decade and billions of dollars per approved drug.
Recursion Pharmaceuticals is not currently profitable, as is common for clinical-stage biotech companies. It generates minimal revenue and invests heavily in research and development to advance its drug pipeline. Investors value such companies based on the potential future revenue from successful drugs, the strength of their intellectual property, and partnerships with larger pharmaceutical firms, rather than on current earnings.
Morgan Stanley's elevated target signals a structural re-rating for Recursion based on its AI platform's validated potential.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.